Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 12, 2026, 8:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 821 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Terminal Diseases Clear all
Completed Not applicable Interventional Results available

A Study to Assess the Tolerability and Efficacy of AKST1210 in Patients on Hemodialysis With Cognitive Impairment

NCT04527328
View directory record Official record
Conditions
Cognitive Impairment, End Stage Renal Disease
Interventions
AKST1210, Sham Control (No Intervention), Hemodialysis
Device · Other · Procedure
Lead sponsor
Alkahest, Inc.
Industry
Eligibility
40 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
4
States / cities
Granada Hills, California • Northridge, California • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Oct 12, 2026, 8:41 PM EDT
Terminated Phase 2 Interventional

HepeX-B in Post Hepatic Allografts for Treatment of End Stage Liver Disease Due to Hepatitis B Infection

NCT00228592
View directory record Official record
Conditions
Hepatitis B, Liver Transplantation
Interventions
HepeX-B, Hepatitis B Immune Globulin (HBIg)
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Rochester, Minnesota + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2007 · Synced Oct 12, 2026, 8:41 PM EDT
Completed Phase 1 Interventional

Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis

NCT02805244
View directory record Official record
Conditions
Anemia of Chronic Kidney Disease
Interventions
JTZ-951, 14C-JTZ-951
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Oct 12, 2026, 8:41 PM EDT
Completed Not applicable Interventional

Evaluation of a Patient Navigation System to Reduce Time to Waitlisting for Potential Kidney Transplant Recipients

NCT01776073
View directory record Official record
Conditions
End-Stage Renal Disease
Interventions
Patient Navigation
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years to 95 Years
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Oct 12, 2026, 8:41 PM EDT
Completed Not applicable Interventional Results available

Does Using a Low Vision Aid Device Improve Quality of Life in Glaucoma Patients?

NCT02526680
View directory record Official record
Conditions
Glaucoma
Interventions
OrCam
Device
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Oct 12, 2026, 8:41 PM EDT
Not yet recruiting Not applicable Interventional

Potassium Containing Salt-Substitute in Hemodialysis-Dependent End Stage Kidney Disease

NCT05558267
View directory record Official record
Conditions
End Stage Kidney Disease
Interventions
Standard Table Salt, Salt Substitute
Dietary Supplement
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 12, 2026, 8:41 PM EDT
Completed Not applicable Interventional

The Home Blood Pressure (BP) Trial

NCT05159999
View directory record Official record
Conditions
End Stage Renal Disease on Dialysis
Interventions
Dry weight target adjustment, Anti-hypertensive medications
Other · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
San Francisco, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 12, 2026, 8:41 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Determine the Safety/Efficacy of Ticagrelor for Maintaining Patency of Arterio-Venous Fistulae Created for Hemodialysis

NCT02335099
View directory record Official record
Conditions
End Stage Renal Disease, Vascular Access Patency
Interventions
ticagrelor, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 85 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Oct 12, 2026, 8:41 PM EDT
Completed Phase 2 Interventional Results available

16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End Stage Renal Disease (ESRD) Requiring Chronic Hemodialysis

NCT02260193
View directory record Official record
Conditions
Anemia, End Stage Renal Disease
Interventions
AKB-6548
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years to 79 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
16
States / cities
El Granada, California • Long Beach, California • San Dimas, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2022 · Synced Oct 12, 2026, 8:41 PM EDT
Completed Not applicable Interventional

Surgical Treatment for Hallux Rigidus

NCT01048450
View directory record Official record
Conditions
Hallux Limitus, Hallux Rigidus
Interventions
Joint Resection- Keller Procedure, Joint Fusion, Hemi-metallic Joint Implant
Radiation · Procedure
Lead sponsor
American College of Foot and Ankle Surgeons
Other
Eligibility
21 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
6
States / cities
Greeley, Colorado • Des Moines, Iowa • Scituate, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2011 · Synced Oct 12, 2026, 8:41 PM EDT
Completed No phase listed Observational

EXtension of Tablo TrEatmeNt Duration Registry

NCT04912050
View directory record Official record
Conditions
End Stage Renal Disease (ESRD), End Stage Renal Disease on Dialysis, Acute Kidney Injury
Interventions
Tablo Hemodialysis System
Device
Lead sponsor
Outset Medical
Industry
Eligibility
Not listed
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 12, 2022 · Synced Oct 12, 2026, 8:41 PM EDT
Completed Phase 4 Interventional Results available

Trial to Optimize Mineral Outcomes in Dialysis Patients

NCT01100723
View directory record Official record
Conditions
Secondary Hyperparathyroidism, Chronic Kidney Disease
Interventions
Cinacalcet, active vitamin D analogue
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Lynchburg, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 2, 2017 · Synced Oct 12, 2026, 8:41 PM EDT
Completed No phase listed Observational

Long Term Treatment of End Stage Renal Disease Patients With Lanthanum Carbonate (Fosrenol)

NCT00567723
View directory record Official record
Conditions
Hyperphosphatemia
Interventions
Not listed
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
2,105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
199
States / cities
Birmingham, Alabama • Hoover, Alabama • Mobile, Alabama + 163 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Oct 12, 2026, 8:41 PM EDT
Completed Phase 3 Interventional

Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-2

NCT05836220
View directory record Official record
Conditions
Secondary Hyperparathyroidism, End Stage Kidney Disease
Interventions
PLS240, Placebo, Open-Label Extension PLS240
Drug
Lead sponsor
Pathalys Pharma
Industry
Eligibility
18 Years to 80 Years
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
50
States / cities
Anaheim, California • Chula Vista, California • Escondido, California + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 12, 2026, 8:41 PM EDT
Recruiting Phase 1 Interventional

CAR-T Cell Therapy for Desensitization in Kidney Transplantation

NCT06056102
View directory record Official record
Conditions
Kidney Transplant, Kidney Failure, End Stage Renal Failure on Dialysis
Interventions
Cyclophosphamide, CART-BCMA, huCART19
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2042
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 12, 2026, 8:41 PM EDT
Completed Phase 1 Interventional

Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma

NCT03068351
View directory record Official record
Conditions
Multiple Myeloma
Interventions
RO6870810, daratumumab
Drug · Biological
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
8
States / cities
Duarte, California • Stanford, California • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2020 · Synced Oct 12, 2026, 8:41 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Analyzing How Genetics May Affect Response to High Blood Pressure Medications

NCT00563901
View directory record Official record
Conditions
Hypertension, Coronary Disease, Cerebrovascular Accident
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
55 Years and older
Enrollment
37,939 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2004
U.S. locations
2
States / cities
Minneapolis, Minnesota • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Oct 12, 2026, 8:41 PM EDT
Completed Phase 2 Interventional Results available

Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Child And Adolescent Outpatients With Major Depressive Disorder

NCT00619619
View directory record Official record
Conditions
Depression, Major Depressive Disorder
Interventions
Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
7 Years to 17 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
9
States / cities
Little Rock, Arkansas • North Miami, Florida • Terre Haute, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2011 · Synced Oct 12, 2026, 8:41 PM EDT
Completed Not applicable Interventional Results available

Pain, Sexual Dysfunction, and Depression in Hemodialysis Patients

NCT00692419
View directory record Official record
Conditions
End Stage Renal Disease, Sexual Dysfunction, Physiological, Pain, Depression
Interventions
Symptom management nurse intervention, Feedback intervention
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 27, 2015 · Synced Oct 12, 2026, 8:41 PM EDT
Completed Phase 4 Interventional

Arterial pH and Total Body Nitrogen Balances in APD

NCT00586131
View directory record Official record
Conditions
End-stage Renal Disease
Interventions
ammonium chloride or sodium citrate/citric acid, Sodium citrate/citratic acid
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Oct 12, 2026, 8:41 PM EDT
Enrolling by invitation No phase listed Observational

VitaSmart HOPE System: Bridge to HOPE Registry

NCT07578441
View directory record Official record
Conditions
End Stage Liver DIsease, Liver Failure
Interventions
hypothermic oxygenated perfusion therapy of a donor liver under standard of care conditions
Device
Lead sponsor
Bridge to Life Ltd.
Industry
Eligibility
Not listed
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 12, 2026, 8:41 PM EDT
Completed Not applicable Interventional Results available

Dialysis Catheter Comparative Clinical Trial

NCT00526123
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Symmetric Tip Catheter, Conventional Split-tip Catheter
Device
Lead sponsor
Tyco Healthcare Group
Industry
Eligibility
18 Years and older
Enrollment
599 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
14
States / cities
Birmingham, Alabama • Phoenix, Arizona • Boston, Massachusetts + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2013 · Synced Oct 12, 2026, 8:41 PM EDT
Withdrawn Not applicable Interventional

Mechanism and the Effect of Midodrine on Portal Pressures in Patients With Cirrhosis

NCT01331785
View directory record Official record
Conditions
Cirrhosis, End Stage Liver Disease, Ascites, Hypotension
Interventions
Midodrine
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 31, 2013 · Synced Oct 12, 2026, 8:41 PM EDT
Completed Not applicable Interventional

Social Networks and Renal Education: Promoting Transplantation

NCT03536858
View directory record Official record
Conditions
End Stage Renal Disease, Living Donor Kidney Transplantation, Renal Dialysis
Interventions
COACH (Communicating about Choices in Transplantation)
Behavioral
Lead sponsor
Temple University
Other
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 12, 2023 · Synced Oct 12, 2026, 8:41 PM EDT